NCT02748018

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 959 (actual)
• Sponsor: Medtronic MiniMed, Inc. · Industry
• Sex: All
• Age: 2 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)

Detailed description

This is a 6 month, multi-center, randomized, parallel, adaptive study in type 1 diabetes with a 6 month continuation period. The study will have three periods, per Cohort: 1. Run-in Period: The run-in period can be up to 60 days during which time a blinded CGM sensor will be worn for two weeks. 2. Study Period: There will be a 6 month randomized study period with two arms: The HCL system and Control. The primary and secondary endpoints will be evaluated during this period only. 3. Continuation Period: There will be a 6 month continuation period during which time all subjects will use the HCL system with Auto Mode. Only the safety endpoint will be evaluated during this period. Up to 1500 subjects will be enrolled in order to have 1000 subjects complete the study. Up to 70 investigational Centers in the US, Europe, Canada, Australia and New Zealand will be enrolled.

Conditions

• Type 1 Diabetes

Interventions

Type	Name	Description
DEVICE	670G and 770G Insulin Pump	Medtronic 670G and 770G Hybrid Closed Loop Systems
DEVICE	Subject's Current Diabetes Therapy	Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).

Timeline

• Start date: 2017-05-25
• Primary completion: 2023-11-01
• Completion: 2023-11-01
• First posted: 2016-04-22
• Last updated: 2025-08-19
• Results posted: 2025-08-19

Locations

36 sites across 9 countries: United States, Canada, France, Germany, Italy, New Zealand, Spain, Sweden, United Kingdom

Regulatory

• FDA-regulated device study